Lori J. Wirth, M.D.

Before closing out their discussion on differentiated thyroid cancer, patients and health care professionals alike consider unmet needs in this space.

A brief discussion on therapeutic options one may consider after progression on lenvatinib therapy for iodine-refractory DTC.

Shared practical advice for patients who may be undergoing treatment for iodine-refractory differentiated thyroid cancer.

Discussion on how best to communicate with care providers while undergoing therapy for iodine-refractory differentiated thyroid cancer.

Considerations for how dosing and dose reductions can be used to optimize use of lenvatinib for iodine-refractory DTC.

Expert and patient perspectives on receiving lenvatinib therapy for iodine-refractory differentiated thyroid cancer.

Health care specialists share insight on the work-up of patients with iodine-refractory differentiated thyroid cancer and how this may affect systemic therapy options.

Discussion on when differentiated thyroid cancer is determined to be iodine-refractory, and how patients should be followed in this setting.

Expert perspectives on the process of surgery and radiation therapy used for less severe cases of differentiated thyroid cancer.

Jim Lesniak shares his experience of receiving a diagnosis of and being treated for differentiated thyroid cancer.

Considerations for the role of patient advocacy groups and patient-to-patient education in the differentiated thyroid cancer journey.

Expert perspectives on the broad management of differentiated thyroid cancer, including surgery, radiation treatment, and systemic therapy.

Health care specialists provide an overview on the nature of differentiated thyroid cancer and discuss subtypes of disease that patients may present with.

High blood pressure is common in patients with thyroid cancer who are taking Lenvima. Here's what one expert says about managing it.